- Home
- MKZR vs KPRX Comparison
MKZR vs KPRX Comparison
Compare MKZR & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKZR
- KPRX
- Stock Information
- Founded
- MKZR 2012
- KPRX 1998
- Country
- MKZR United States
- KPRX United States
- Employees
- MKZR N/A
- KPRX N/A
- Industry
- MKZR
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MKZR
- KPRX Health Care
- Exchange
- MKZR Nasdaq
- KPRX Nasdaq
- Market Cap
- MKZR 10.3M
- KPRX 9.2M
- IPO Year
- MKZR N/A
- KPRX N/A
- Fundamental
- Price
- MKZR $4.92
- KPRX $2.35
- Analyst Decision
- MKZR
- KPRX Strong Buy
- Analyst Count
- MKZR 0
- KPRX 1
- Target Price
- MKZR N/A
- KPRX $10.00
- AVG Volume (30 Days)
- MKZR 42.8K
- KPRX 50.7K
- Earning Date
- MKZR 11-18-2025
- KPRX 11-07-2025
- Dividend Yield
- MKZR 20.49%
- KPRX N/A
- EPS Growth
- MKZR N/A
- KPRX N/A
- EPS
- MKZR N/A
- KPRX N/A
- Revenue
- MKZR $21,294,932.00
- KPRX N/A
- Revenue This Year
- MKZR N/A
- KPRX N/A
- Revenue Next Year
- MKZR N/A
- KPRX N/A
- P/E Ratio
- MKZR N/A
- KPRX N/A
- Revenue Growth
- MKZR 21.25
- KPRX N/A
- 52 Week Low
- MKZR $3.89
- KPRX $2.21
- 52 Week High
- MKZR $55.00
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- MKZR 44.65
- KPRX 39.68
- Support Level
- MKZR $4.80
- KPRX $2.22
- Resistance Level
- MKZR $5.60
- KPRX $2.55
- Average True Range (ATR)
- MKZR 0.46
- KPRX 0.18
- MACD
- MKZR -0.02
- KPRX -0.02
- Stochastic Oscillator
- MKZR 22.45
- KPRX 23.40
About MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.